Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A perspective on pancreatic stem/progenitor cells.

Joel F Habener1

  • 1Laboratory of Molecular Endocrinology, Massachusetts General Hospital, 55 Fruit Street - WEL 320, Boston, MA 02114, USA. jhabener@partners.org

Pediatric Diabetes
|December 17, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery, characterization, and clinical development of the glucagon-like peptides.

The Journal of clinical investigation·2017
Same author

Pancreas and Not Gut Mediates the GLP-1-Induced Glucoincretin Effect.

Cell metabolism·2017
Same author

Evolving function and potential of pancreatic alpha cells.

Best practice & research. Clinical endocrinology & metabolism·2015
Same author

Does GLP-1 suppress its own basal secretion?

Endocrine research·2015
Same author

GLP-1(32-36)amide Pentapeptide Increases Basal Energy Expenditure and Inhibits Weight Gain in Obese Mice.

Diabetes·2015
Same author

GLP-1(32-36)amide, a novel pentapeptide cleavage product of GLP-1, modulates whole body glucose metabolism in dogs.

Peptides·2014
Same journal

Mapping Lifestyle Factors in Blood Glucose Variability in Adolescents With Type 1 Diabetes Mellitus: A Pilot Study.

Pediatric diabetes·2026
Same journal

Achieving Glycemic Targets in and out-of-School: Real-World Data From 1341 Italian Children Using the MiniMed 780G System During Auto Mode.

Pediatric diabetes·2026
Same journal

Sex-Specific BMI Trajectories in Young People With Type 1 Diabetes: A 20-Year Retrospective Regional Audit.

Pediatric diabetes·2026
Same journal

Treatment of Youth-Onset Type 2 Diabetes: Focus on SGLT-2 Inhibitor Use.

Pediatric diabetes·2026
Same journal

Pediatric Hepatocyte Nuclear Factor 1B (<i>HNF1B</i>) Disease: Diabetes and Endocrine Manifestations.

Pediatric diabetes·2026
Same journal

Epidemiological Trends and Seasonal Patterns in Childhood Type 1 Diabetes: Insights From 2001 to 2024 in Lithuania.

Pediatric diabetes·2026
See all related articles

Cell-based therapies, including stem cells, show promise for curing type 1 and type 2 diabetes by regenerating insulin-producing cells. This regenerative medicine approach offers a potential permanent solution beyond current diabetes management. Keywords: stem cells, diabetes cure, regenerative medicine, insulin-producing cells.

Area of Science:

  • Regenerative Medicine
  • Endocrinology
  • Cellular Therapy

Background:

  • Type 1 and type 2 diabetes mellitus prevalence is rising globally, leading to significant morbidity and mortality.
  • Current treatments manage diabetes but do not offer a cure, highlighting the need for novel therapeutic strategies.
  • Pancreatic islet transplantation shows potential but is limited by donor organ scarcity.

Purpose of the Study:

  • To explore the potential of cell-based therapies and regenerative medicine for achieving a permanent cure for diabetes.
  • To discuss the application of stem cells in generating functional, insulin-producing beta-cells for transplantation.
  • To consider future directions in stem cell administration for islet regeneration.

Main Methods:

  • Utilizing embryo-derived or adult tissue-derived stem cells (from pancreas, liver, bone marrow) for in vitro expansion and differentiation into islet-like clusters.

Related Experiment Videos

  • Transplanting these differentiated cells into streptozotocin-induced diabetic mice to assess glycemic control.
  • Investigating strategies for direct stem cell administration or stem cell stimulator use to enhance endogenous pancreatic stem cells.

    • Main Results:

    • Stem cells can be expanded and differentiated into insulin-producing islet-like clusters.
    • Transplanted cells have demonstrated the ability to achieve glycemic control in diabetic mouse models.
    • Potential exists for in vivo regeneration of injured islets through targeted stem cell therapy.

    Conclusions:

    • Cellular medicines and regenerative medicine offer a promising pathway toward a functional cure for diabetes.
    • Stem cell-derived therapies can overcome the limitations of donor islet availability.
    • Future research may focus on systemic stem cell delivery or stimulation of endogenous repair mechanisms for diabetes treatment.